Plain-English translation of NCT04299724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial of the Covid-19/aAPC vaccine, which is made from special immune cells that have been genetically modified to recognize and fight the coronavirus. Researchers want to see if the vaccine is safe to use and whether it helps your body build immunity against COVID-19. You would receive three injections of these cells under your skin over four weeks, with follow-up blood tests to monitor your safety and immune response.
When this trial began, there were no approved vaccines or proven treatments for COVID-19, and the virus was spreading rapidly worldwide. This trial exists to see if this new approach—using engineered immune cells to train your body to fight the virus—could be a safe and effective way to prevent or treat COVID-19 infection.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic three times (at the start, two weeks later, and four weeks later) to receive injections of the vaccine under your skin. Blood tests would be done at five time points over two months to check for any side effects and to measure how well your immune system is responding. The entire trial lasts about two months from your first injection to your final follow-up.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
China